BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24321392)

  • 1. Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.
    Fan C; Gao S; Hui Z; Liang J; Lv J; Wang X; He J; Wang L
    Radiat Oncol; 2013 Dec; 8():286. PubMed ID: 24321392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.
    Borghetti P; Barbera F; Bonù ML; Trevisan F; Ciccarelli S; Vitali P; Maddalo M; Triggiani L; Pasinetti N; Pedretti S; Bonetti B; Pariscenti G; Tironi A; Caprioli A; Buglione M; Magrini SM
    Radiol Med; 2016 Sep; 121(9):696-703. PubMed ID: 27230669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
    Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
    Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
    [No Abstract]   [Full Text] [Related]  

  • 4. Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.
    Jin J; Xu Y; Hu X; Chen M; Fang M; Hang Q; Chen M
    Curr Oncol; 2020 Jun; 27(3):e283-e293. PubMed ID: 32669935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival.
    Varlotto JM; Yao AN; DeCamp MM; Ramakrishna S; Recht A; Flickinger J; Andrei A; Reed MF; Toth JW; Fizgerald TJ; Higgins K; Zheng X; Shelkey J; Medford-Davis LN; Belani C; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):765-73. PubMed ID: 25752390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
    Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
    Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
    Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.
    Matsuguma H; Nakahara R; Ishikawa Y; Suzuki H; Inoue K; Katano S; Yokoi K
    Interact Cardiovasc Thorac Surg; 2008 Aug; 7(4):573-7. PubMed ID: 18413349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
    Moretti L; Yu DS; Chen H; Carbone DP; Johnson DH; Keedy VL; Putnam JB; Sandler AB; Shyr Y; Lu B
    Oncologist; 2009 Nov; 14(11):1106-15. PubMed ID: 19897534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
    Sawyer TE; Bonner JA; Gould PM; Foote RL; Deschamps C; Trastek VF; Pairolero PC; Allen MS; Shaw EG; Marks RS; Frytak S; Lange CM; Li H
    Cancer; 1997 Oct; 80(8):1399-408. PubMed ID: 9338463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysis.
    Mantovani C; Levra NG; Filippi AR; Novello S; Buffoni L; Ragona R; Ricardi U
    Clin Lung Cancer; 2013 Mar; 14(2):194-9. PubMed ID: 22885347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
    Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
    J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.
    Yuan M; Men Y; Kang J; Sun X; Zhao M; Bao Y; Yang X; Sun S; Ma Z; Wang J; Deng L; Wang W; Zhai Y; Liu W; Zhang T; Wang X; Bi N; Lv J; Liang J; Feng Q; Chen D; Xiao Z; Zhou Z; Wang L; Hui Z
    Thorac Cancer; 2021 Jan; 12(2):227-234. PubMed ID: 33247556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.
    Fujimoto T; Cassivi SD; Yang P; Barnes SA; Nichols FC; Deschamps C; Allen MS; Pairolero PC
    J Thorac Cardiovasc Surg; 2006 Sep; 132(3):499-506. PubMed ID: 16935101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local failure in resected N1 lung cancer: implications for adjuvant therapy.
    Higgins KA; Chino JP; Berry M; Ready N; Boyd J; Yoo DS; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):727-33. PubMed ID: 22208965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non-Small Cell Lung Cancer.
    Wang EH; Corso CD; Park HS; Chen AB; Wilson LD; Kim AW; Decker RH; Yu JB
    Am J Clin Oncol; 2018 Feb; 41(2):152-158. PubMed ID: 26523443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.
    Lopez Guerra JL; Gomez DR; Lin SH; Levy LB; Zhuang Y; Komaki R; Jaen J; Vaporciyan AA; Swisher SG; Cox JD; Liao Z; Rice DC
    Ann Oncol; 2013 Jan; 24(1):67-74. PubMed ID: 23002278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of postoperative radiotherapy in multimodality treatment of resected small-cell lung cancer with lymph node metastasis.
    Liu WS; Zhao LJ; Wang S; Gong LL; Liu ZY; Yuan ZY; Wang P
    Eur J Surg Oncol; 2014 Sep; 40(9):1156-62. PubMed ID: 24655801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.